AstraZeneca PLC closed 21.95% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca PLC closed 20.63% short of its 52-week high of £133.88, which the company achieved on September 3rd.

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

More AZN analysis All earnings call transcripts AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript© Provided by The Motley Fool Logo of jester cap with thought bubble.© The Motley Fool ...

AstraZeneca Plc agreed to buy Icosavax Inc. for as much as $1.1 billion to gain a developer of innovative vaccines for respiratory viruses.

Parnassus Growth Equity Fund highlighted stocks like AstraZeneca PLC (NASDAQ:AZN) in the second quarter 2024 investor letter. AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that ...

American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a ...

(RTTNews) - British drug major AstraZeneca PLC (AZN.L) reported Thursday that its third-quarter profit before tax was $922 million, compared to last year's loss of $2.00 billion.